The European Medicines Agency approved 39 new cancer drugs between 2009 and 2013 despite having no evidence that they worked, unnecessarily exposing patients to toxicity, researchers said Thursday (5 October).
In assessing the relocation of the EU drugs agency EMA, old member states have a "moral and political obligation" to give an advantage to those candidate countries that do not currently host another EU agency, Croatia’s health minister told EURACTIV.com.
Athens’ decision to claim the European Medicine Agency's relocation from London sends a message that medicine is “not just a commodity but a social good”, Greece’s Alternate Minister of Foreign Affairs, Georgios Katrougalos, told EURACTIV.com.
The Southern EU member states are exploring the possibility of forming a united camp regarding the relocation of the European Medicines Agency from London after Brexit, Greece’s Deputy Foreign Minister George Katrougalos said.
The European Medicines Agency (EMA) presented on Tuesday (1 August) a business continuity plan aimed at tackling the potential challenges poised by its relocation from London to another member state after the Brexit decision.
Hosting the European Medicines Agency brings considerable economic benefits to the host city as the service employs more than 1,000 people, paid by the EU. Athens and Milan are keen to secure a slice of this lucrative pie.
The European Medicines Agency (EMA) is not a toy to be played with by politicians, Edith Schippers told EURACTIV.com. The decision on the agency's relocation should be based on the European Commission's assessment, she argues in an interview.
EU leaders should make a patient-oriented decision on the relocation of the European Medicines Agency (EMA) from London and ensure “minimal disruption”, according to the pharmaceutical industry and consumer groups.
EU member states are urged to put on a united front on the issue of relocating the London-based European Medicines Agency (EMA), rather than bicker publicly and give the UK government reason to believe the bloc cannot cooperate properly, diplomats have told EURACTIV.com.
Any country that wants to inherit the European Medicines Agency (EMA) from London has to be easily accessible. Candidates will also need to increase their national agency’s resources, as staff are expected to move to the EMA, according to Adrian van den Hoven.
Last month, EU Council President Donald Tusk and European Commission chief Jean-Claude Juncker presented the procedure for relocating the European Bank Authority (EBA) and the European Medicines Agency (EMA) from the UK after it leaves the EU.
The debate over where to relocate the London-based European Medicines Agency (EMA) after Brexit has divided the other 27 EU member states, despite calls for an urgent decision from the drugs industry and patient groups.
Leaders of 27 EU member states - excluding the UK -agreed late on Thursday (22 June) on criteria to decide by November the new seats of the European Medicines Agency and the European Banking Authority, which are currently based in London.
Spanish Minister for Health Dolors Montserrat said today (24 May) that Barcelona is “first in the class” in meeting all the criteria to host the European Medicines Agency (EMA). She also insisted that the central government supports Catalonia's bid to host it after Brexit.
Portugal is the latest member state to try and poach the UK-based European Medicines Agency after Brexit. In an interview with EURACTIV.com, Portugal’s junior minister for European affairs insisted having two EU agencies based in Lisbon already would not hurt its chances.
The future of EU agencies based in London will be part of tomorrow’s EU-27 summit, an issue that could erode the unity that European leaders want to showcase before the divorce talks with the UK begin.
Pharmaceutical companies called on Thursday (27 April) for a phased transition in drug regulation after Britain leaves the European Union, in order to avoid supply disruption and protect public health.